<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1268">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01799239</url>
  </required_header>
  <id_info>
    <org_study_id>CP237</org_study_id>
    <nct_id>NCT01799239</nct_id>
  </id_info>
  <brief_title>Safety and Performance of Newly Developed 1-piece Ostomy Product Compared With SenSura</brief_title>
  <official_title>Investigating the Safety and Performance of Newly Developed 1-piece Ostomy Product Concept Compared With SenSura 1-piece in Subjects With an Ileostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current investigation is to evaluate the combination of an adhesive with a
      soft top film.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Leakage (Percentage of All Baseplates With Leakage)</measure>
    <time_frame>After each baseplate change over a period, of 7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>leakage is measured using a 4-point leakage scale developed by Coloplast A/S at every baseplate change.
The subjects tick of one of the four possible answers:
No leakage
Starting to leak
Leakage
Sudden leakage</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Ileostomy - Stoma</condition>
  <arm_group>
    <arm_group_label>First Test product; then SenSura</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject in this arm first test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details.
After cross-over the subject test SenSura which is CE-marked and commerical available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First SenSura, Then Test product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subject in this arm first test SenSura which is CE-marked and commerical available.
After cross-over the subject test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test product</intervention_name>
    <description>The test product consists of an adhesive with a new top film</description>
    <arm_group_label>First Test product; then SenSura</arm_group_label>
    <arm_group_label>First SenSura, Then Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SenSura</intervention_name>
    <description>SenSura is the CE-marked and commercially available comparator product</description>
    <arm_group_label>First Test product; then SenSura</arm_group_label>
    <arm_group_label>First SenSura, Then Test product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have given written informed consent

          2. Be at least 18 years of age and have full legal capacity

          3. Be able to handle the bags themselves

          4. Have an ileostomy with a diameter between 15 and 55 mm

          5. Have had their ileostomy for at least 3 months

          6. Currently use a 1-piece flat ostomy appliance with open bag

          7. Use minimum 1 product every second day, i.e. maximum 2 days wear time

          8. Be suitable for participation in the study and for using a standard adhesive, flat
             base plate

          9. Must be able and willing to use custom cut products

         10. Accept to test two 1-piece products within the study period

        Exclusion Criteria:

          1. Use irrigation during the study period (flush the intestines with water)

          2. Currently receiving or have within the past 2 months received chemotherapy or
             radiation therapy

          3. Currently receiving or have within the past month received systematic steroid or
             local treatment in the peristomal area

          4. Are pregnant or breastfeeding

          5. Participating in other interventional clinical investigations or have previously
             participated in this investigation

          6. Currently using a ostomy belt

          7. Currently using extended wear product

          8. Have a loop ileostomy

          9. Known hypersensitivity towards any of the test products

         10. Suffering from severe peristomal skin problems prior to participation in the
             investigation (assessed by the study nurse)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Carter, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Coloplast A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skövde Hospital</name>
      <address>
        <city>Skövde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>February 22, 2013</firstreceived_date>
  <firstreceived_results_date>October 7, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stoma ileostomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The subjects were recruited from hospital sites in Sweden and in Germany subjects were recruit from the Coloplast database and from hospital sites.</recruitment_details>
      <pre_assignment_details>The investigation was designed as a cross-over study where subjects that did not complete the 1 period as planned were allowed to continue to the next test period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>First Test Product; Then SenSura</title>
        </group>
        <group group_id="P2">
          <title>First SenSura, Then Test Product</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">It was uncertain in which order the product were tested for 1 subject. Subject is excl from analysis</participants>
                <participants group_id="P2" count="16">It was uncertain in which order the product were tested for 1 subject. Subject is excl from analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Three subjects were excluded from the intention to treat (ITT) population. Two of the were inclusion criteria violaters; 1 convex user and 1 colostomist. with the last subject it was uncertain in which order the subject tested the test products. the subejct was excluded from the analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Describing baseline data for all subjects in the ITT population</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57.6" spread="15.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Leakage (Percentage of All Baseplates With Leakage)</title>
        <description>leakage is measured using a 4-point leakage scale developed by Coloplast A/S at every baseplate change.
The subjects tick of one of the four possible answers:
No leakage
Starting to leak
Leakage
Sudden leakage</description>
        <time_frame>After each baseplate change over a period, of 7 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>The new test product is a 1-piece open ostomy product with the intended use being collecting output from an ileostomy.</description>
          </group>
          <group group_id="O2">
            <title>SenSura</title>
            <description>CE marked and launched SenSura used in this investigation is a 1-piece open appliance with the intended use being to collect output from an ileostomy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Baseplates analyzed</title>
            <units>Baseplates</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="184"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Leakage (Percentage of All Baseplates With Leakage)</title>
            <description>leakage is measured using a 4-point leakage scale developed by Coloplast A/S at every baseplate change.
The subjects tick of one of the four possible answers:
No leakage
Starting to leak
Leakage
Sudden leakage</description>
            <units>percentage baseplates with leakage</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>The new test product is a 1-piece open ostomy product with the intended use being collecting output from an ileostomy.</description>
        </group>
        <group group_id="E2">
          <title>SenSura</title>
          <description>CE marked and launched SenSura used in this investigation is a 1-piece open appliance with the intended use being to collect output from an ileostomy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain in the peristomal area</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Itching in the peristomal area</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>red skin in the peristomal area</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Camilla Felsvang Vibjerg, Senior Clinical manager</name_or_title>
      <organization>Coloplast A/S</organization>
      <phone>+45 4911 1990</phone>
      <email>dkcfv@coloplast.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
